PillRx only · Gel · Rectal
Diazepam
Diazepam
4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US11 NDCs
4 active makers
4 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$196.399
Latest avg · Jul 22, 2026
-11%
Since Dec 17, 2025
4
Active US suppliers
55%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
341
Rx · 2026 Q1
559
Units dispensed
-99%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it4 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Zydus Pharmaceuticals USA Inc. | unknown | 3 | SUPPLYING |
| Navinta LLC | unknown | 3 | SUPPLYING |
| Oceanside Pharmaceuticals | unknown | 3 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 10, 2018RECALLRecall (Class III): Diazepam Rectal Gel, 2.5 mg, TWIN PACK that Contains two pre-filled, unit-dose, rectal delivery systems with lubricatin…
Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton. — Recalling firm: Valeant Pharmaceuticals North America LLC — Nationwide in the USA